BIOMAT Database Logo BIOMAT Database Logo

Design and Synthesis of 2-(1-Alkylaminoalkyl)pyrazolo[1,5-a]pyrimidines as New Respiratory Syncytial Virus Fusion Protein Inhibitors. 2020

Toru Yamaguchi-Sasaki, and Yunoshin Tamura, and Yuya Ogata, and Takanori Kawaguchi, and Jun Kurosaka, and Yutaka Sugaya, and Kanako Iwakiri, and Tsuyoshi Busujima, and Ryo Takahashi, and Naoko Ueda-Yonemoto, and Eiji Tanigawa, and Tomoko Abe-Kumasaka, and Hiroyuki Sugiyama, and Kosuke Kanuma
Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd.

Respiratory syncytial virus (RSV) is one of the most common causes of lower respiratory tract infections and a significant pathogen for both adults and children. Although two drugs have been approved for the treatment of RSV infections, the low therapeutic index of these drugs have led pharmaceutical companies to develop safe and effective small-molecule anti-RSV drugs. The pyrazolo[1,5-a]pyrimidine series of compounds containing a piperidine ring at the 2-position of the pyrazolo[1,5-a]pyrimidine scaffold are known as candidate RSV fusion (F) protein inhibitor drugs, such as presatovir and P3. The piperidine ring has been revealed to facilitate the formation of an appropriate dihedral angle between the pyrazolo[1,5-a]pyrimidine scaffold and the plane of the amide bond for exertion of anti-RSV activity. A molecular-dynamic study on newly designed compounds with an acyclic chain instead of the piperidine ring proposed and demonstrated a new series of pyrazolo[1,5-a]pyrimidine derivatives, such as 9c with a 1-methyaminopropyl moiety, showing similar dihedral angle distributions to those in presatovir. Compound 9c exhibited potent anti-RSV activity with an EC50 value of below 1 nM, which was similar to that of presatovir. A subsequent optimization study on the benzene ring of 9c led to the potent RSV F protein inhibitor 14f with an EC50 value of 0.15 nM. The possibility of improving the biological properties of anti-RSV agents by modification at the 7-position of pyrazolo[1,5-a]pyrimidine is also discussed.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D013237 Stereoisomerism The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Molecular Stereochemistry,Stereoisomers,Stereochemistry, Molecular,Stereoisomer
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

Toru Yamaguchi-Sasaki, and Yunoshin Tamura, and Yuya Ogata, and Takanori Kawaguchi, and Jun Kurosaka, and Yutaka Sugaya, and Kanako Iwakiri, and Tsuyoshi Busujima, and Ryo Takahashi, and Naoko Ueda-Yonemoto, and Eiji Tanigawa, and Tomoko Abe-Kumasaka, and Hiroyuki Sugiyama, and Kosuke Kanuma
Design, synthesis and bioevaluation of 2,7-diaryl-pyrazolo[1,5-a]pyrimidines as tubulin polymerization inhibitors.
October 2021, Bioorganic chemistry,
Toru Yamaguchi-Sasaki, and Yunoshin Tamura, and Yuya Ogata, and Takanori Kawaguchi, and Jun Kurosaka, and Yutaka Sugaya, and Kanako Iwakiri, and Tsuyoshi Busujima, and Ryo Takahashi, and Naoko Ueda-Yonemoto, and Eiji Tanigawa, and Tomoko Abe-Kumasaka, and Hiroyuki Sugiyama, and Kosuke Kanuma
Design and synthesis of certain 7-Aryl-2-Methyl-3-Substituted Pyrazolo{1,5-a}Pyrimidines as multikinase inhibitors.
December 2023, European journal of medicinal chemistry,
Toru Yamaguchi-Sasaki, and Yunoshin Tamura, and Yuya Ogata, and Takanori Kawaguchi, and Jun Kurosaka, and Yutaka Sugaya, and Kanako Iwakiri, and Tsuyoshi Busujima, and Ryo Takahashi, and Naoko Ueda-Yonemoto, and Eiji Tanigawa, and Tomoko Abe-Kumasaka, and Hiroyuki Sugiyama, and Kosuke Kanuma
Synthesis and SAR of a new series of COX-2-selective inhibitors: pyrazolo[1,5-a]pyrimidines.
February 2001, Journal of medicinal chemistry,
Toru Yamaguchi-Sasaki, and Yunoshin Tamura, and Yuya Ogata, and Takanori Kawaguchi, and Jun Kurosaka, and Yutaka Sugaya, and Kanako Iwakiri, and Tsuyoshi Busujima, and Ryo Takahashi, and Naoko Ueda-Yonemoto, and Eiji Tanigawa, and Tomoko Abe-Kumasaka, and Hiroyuki Sugiyama, and Kosuke Kanuma
Synthesis of a new series of pyrazolo[1,5-a]pyrimidines as CDK2 inhibitors and anti-leukemia.
December 2021, Bioorganic chemistry,
Toru Yamaguchi-Sasaki, and Yunoshin Tamura, and Yuya Ogata, and Takanori Kawaguchi, and Jun Kurosaka, and Yutaka Sugaya, and Kanako Iwakiri, and Tsuyoshi Busujima, and Ryo Takahashi, and Naoko Ueda-Yonemoto, and Eiji Tanigawa, and Tomoko Abe-Kumasaka, and Hiroyuki Sugiyama, and Kosuke Kanuma
Structure-guided design of pyrazolo[1,5-a]pyrimidines as inhibitors of human cyclin-dependent kinase 2.
February 2005, Bioorganic & medicinal chemistry letters,
Toru Yamaguchi-Sasaki, and Yunoshin Tamura, and Yuya Ogata, and Takanori Kawaguchi, and Jun Kurosaka, and Yutaka Sugaya, and Kanako Iwakiri, and Tsuyoshi Busujima, and Ryo Takahashi, and Naoko Ueda-Yonemoto, and Eiji Tanigawa, and Tomoko Abe-Kumasaka, and Hiroyuki Sugiyama, and Kosuke Kanuma
Design and synthesis of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines as potent CRF1 receptor antagonists.
August 2004, Bioorganic & medicinal chemistry letters,
Toru Yamaguchi-Sasaki, and Yunoshin Tamura, and Yuya Ogata, and Takanori Kawaguchi, and Jun Kurosaka, and Yutaka Sugaya, and Kanako Iwakiri, and Tsuyoshi Busujima, and Ryo Takahashi, and Naoko Ueda-Yonemoto, and Eiji Tanigawa, and Tomoko Abe-Kumasaka, and Hiroyuki Sugiyama, and Kosuke Kanuma
Design, synthesis, and evaluation of 2-aryl-7-(3',4'-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidines as novel PDE-4 inhibitors.
February 2010, Bioorganic & medicinal chemistry letters,
Toru Yamaguchi-Sasaki, and Yunoshin Tamura, and Yuya Ogata, and Takanori Kawaguchi, and Jun Kurosaka, and Yutaka Sugaya, and Kanako Iwakiri, and Tsuyoshi Busujima, and Ryo Takahashi, and Naoko Ueda-Yonemoto, and Eiji Tanigawa, and Tomoko Abe-Kumasaka, and Hiroyuki Sugiyama, and Kosuke Kanuma
Preparation and optimization of pyrazolo[1,5-a]pyrimidines as new potent PDE4 inhibitors.
January 2016, Bioorganic & medicinal chemistry letters,
Toru Yamaguchi-Sasaki, and Yunoshin Tamura, and Yuya Ogata, and Takanori Kawaguchi, and Jun Kurosaka, and Yutaka Sugaya, and Kanako Iwakiri, and Tsuyoshi Busujima, and Ryo Takahashi, and Naoko Ueda-Yonemoto, and Eiji Tanigawa, and Tomoko Abe-Kumasaka, and Hiroyuki Sugiyama, and Kosuke Kanuma
Synthesis of New Bis(pyrazolo[1,5-a]pyrimidines) Linked to Different Spacers as Potential MurB Inhibitors.
June 2023, Chemistry & biodiversity,
Toru Yamaguchi-Sasaki, and Yunoshin Tamura, and Yuya Ogata, and Takanori Kawaguchi, and Jun Kurosaka, and Yutaka Sugaya, and Kanako Iwakiri, and Tsuyoshi Busujima, and Ryo Takahashi, and Naoko Ueda-Yonemoto, and Eiji Tanigawa, and Tomoko Abe-Kumasaka, and Hiroyuki Sugiyama, and Kosuke Kanuma
Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2.
November 2007, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!